• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Remicade does well in study on inflammation

Washington, D.C. - In a recent 10-week, three-dose phase II trial of inflaximab (Remicade), 87.9 percent of the 250 participants achieved PASI 75, while 58 percent achieved PASI 90 at the 10-week mark.

Related Videos
3 experts are featured in this series.
Related Content
Review Compares Psoriasis Therapies in Asian Populations
November 22nd 2024

Review Compares Psoriasis Therapies in Asian Populations

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Subgroup Analysis Reveals Equal Benefit of Brodalumab in Obese vs Non-Obese Patients With Psoriasis
November 22nd 2024

Subgroup Analysis Reveals Equal Benefit of Brodalumab in Obese vs Non-Obese Patients With Psoriasis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Patients Treated for Acne Exhibit Higher Sebum, Hydration, and TEWL Levels than General Population
November 22nd 2024

Patients Treated for Acne Exhibit Higher Sebum, Hydration, and TEWL Levels than General Population

Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases
November 22nd 2024

Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases

© 2024 MJH Life Sciences

All rights reserved.